Compounding HRT Solutions for Addison's Disease Support Patients

According to NIH MedlinePlus and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), fatigue in Addison's disease is often profound and persistent, marked by overwhelming tiredness and loss of stamina that worsens with minimal exertion and may not improve with rest. It commonly coexists with muscle weakness, lightheadedness on standing, slowed thinking, and reduced ability to complete usual tasks, producing a steady, daily limitation in energy and function. Patients experiencing these symptoms should seek evaluation from a qualified clinician; sudden severe symptoms — including severe weakness, vomiting, low blood pressure, or confusion — may indicate an adrenal crisis and require urgent medical attention.

According to NIH MedlinePlus and NIDDK, in Addison's disease unintentional weight loss is common and often gradual; it reflects reduced appetite, persistent nausea, vomiting, abdominal discomfort, frequent salt cravings and losses, and chronic fatigue. Cortisol deficiency increases protein breakdown and reduces energy, producing muscle wasting and diminished exercise tolerance, while low aldosterone causes sodium loss and low blood pressure that further suppress appetite and body weight. Patients experiencing these symptoms should seek evaluation from a qualified clinician; sudden severe symptoms such as severe weakness, vomiting, low blood pressure, or confusion may indicate an adrenal crisis and require urgent medical attention.

According to NIH MedlinePlus and NIDDK, in Addison's disease abdominal pain is often diffuse, crampy, or colicky and may be severe enough to mimic a surgical acute abdomen, often with generalized tenderness. It commonly occurs with nausea, vomiting, bloating, and weight loss, and may reflect electrolyte abnormalities such as hyponatremia, hyperkalemia, or hypotension, which may indicate impending adrenal crisis. Patients experiencing sudden or severe abdominal pain alongside weakness, vomiting, low blood pressure, or confusion should seek urgent medical attention, as these symptoms may indicate an adrenal crisis requiring emergency care.

According to NIH MedlinePlus and NIDDK, in Addison's disease lightheadedness or spells of near-fainting present as sudden weakness, blurred vision, sweating, paleness, and mental dulling, and may progress to collapse. They often follow standing, exertion, or intercurrent illness and result from orthostatic hypotension due to low cortisol, aldosterone-mediated salt loss with hyponatremia, and from hypoglycemia, which may precede an adrenal crisis. Patients who experience syncope or sudden severe symptoms — including severe weakness, vomiting, low blood pressure, or confusion — should seek urgent medical attention immediately.

According to the FDA-approved prescribing information for hydrocortisone, hydrocortisone is a synthetic glucocorticoid indicated for conditions requiring glucocorticoid replacement, including primary adrenal insufficiency (Addison's disease). The labeling describes physiologic glucocorticoid replacement, with oral and parenteral administration routes per labeling. Per the labeling, patients receiving hydrocortisone replacement require individualized dosing with increased doses during physiologic stress such as illness, surgery, or trauma (stress dosing), and monitoring for signs of adrenal insufficiency or excess. Any compounded preparation involving hydrocortisone is not reviewed by FDA for safety or effectiveness before dispensing. Commercially available hydrocortisone products are separately regulated; clinical decisions belong with the prescribing endocrinologist.

According to the FDA-approved prescribing information for dexamethasone, dexamethasone is a potent, long-acting synthetic glucocorticoid indicated for endocrine disorders including primary adrenal insufficiency and adrenal crisis. The labeling describes glucocorticoid replacement with negligible mineralocorticoid activity, with oral, intravenous, and intramuscular administration routes per labeling. According to the FDA-approved prescribing information for dexamethasone and the Endocrine Society Clinical Practice Guideline on Primary Adrenal Insufficiency, dexamethasone has negligible mineralocorticoid activity, so patients with Addison's disease managed on dexamethasone are typically also prescribed a separate mineralocorticoid such as fludrocortisone by their prescribing endocrinologist. Per the labeling, monitoring for glucocorticoid side effects and dose adjustment during physiologic stress are required. Any compounded preparation involving dexamethasone is not reviewed by FDA for safety or effectiveness before dispensing. Commercially available dexamethasone products are separately regulated; clinical decisions belong with the prescribing endocrinologist.